Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (17058)	12/18/1998 6:26:00 PM
From: EyeDrMike	Read Replies (4) \| Respond to of 23519

MK, plenty of doubts here, or did you miss 1998? any idea if there's cash on hand to support operations, and if so, for how long? That 8 million milestone, when it comes, will probably be long spent. M

To: Mkilloran who wrote (17058)	12/18/1998 6:32:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

Did anyone see the piece done by CNBC after the close on biotechnology stocks? They made the following statements: That there are approximately 300 publicly traded biotech stocks. That most do not even have an approved product. That analyst estimate that most do not currently have enough cash reserves to continue their R&D expenses through 1999. That analysts estimate that about 250 of these companies will probably either be taken over or go out of business. All these things considered, I believe that as a small cap biotech company Vivus has one of the most promising futures to be able to survive and whose product sales will easily cover its R&D costs. Most of all I believe that it is one of the few biotech companies that will SHOW SUBSTANTIAL PROFITS IN 1999. A viable small cap biotech stock that has an approved product in an expanding market makes Vivus the stock with the most potential for appreciation in 1999. But with Leland Wilson at the helm who really knows.